Zacks Research Has Strong Estimate for Medifast Q1 Earnings

Medifast, Inc. (NYSE:MED) – Equities research analysts at Zacks Research lifted their Q1 2025 EPS estimates for Medifast in a report released on Monday, March 10th. Zacks Research analyst R. Department now anticipates that the specialty retailer will earn ($0.07) per share for the quarter, up from their prior estimate of ($0.10). The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q4 2025 earnings at $0.53 EPS, FY2025 earnings at $1.04 EPS, Q3 2026 earnings at $0.39 EPS and Q4 2026 earnings at $0.49 EPS.

Separately, DA Davidson cut their price target on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th.

Medifast Trading Down 1.9 %

Shares of MED opened at $14.06 on Thursday. The stock has a market capitalization of $153.79 million, a P/E ratio of 78.11 and a beta of 1.13. The firm’s fifty day simple moving average is $15.32 and its two-hundred day simple moving average is $17.45. Medifast has a 12 month low of $13.57 and a 12 month high of $39.14.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.26. The business had revenue of $119.00 million for the quarter, compared to analysts’ expectations of $114.25 million. Medifast had a net margin of 0.35% and a return on equity of 10.64%.

Hedge Funds Weigh In On Medifast

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. boosted its position in shares of Medifast by 28.8% during the 4th quarter. Federated Hermes Inc. now owns 279,473 shares of the specialty retailer’s stock worth $4,924,000 after purchasing an additional 62,574 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Medifast by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 245,929 shares of the specialty retailer’s stock worth $4,335,000 after purchasing an additional 1,447 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Medifast by 3.4% during the 4th quarter. American Century Companies Inc. now owns 244,185 shares of the specialty retailer’s stock worth $4,303,000 after purchasing an additional 8,058 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Medifast by 11.4% during the 4th quarter. Two Sigma Investments LP now owns 232,069 shares of the specialty retailer’s stock worth $4,089,000 after purchasing an additional 23,822 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its position in shares of Medifast by 86.0% during the 4th quarter. Two Sigma Advisers LP now owns 216,000 shares of the specialty retailer’s stock worth $3,806,000 after purchasing an additional 99,900 shares in the last quarter. Institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.